Treatment for AIHA Partially Responsive to Steroids
For autoimmune hemolytic anemia (AIHA) that shows only partial response to corticosteroids, add rituximab to ongoing steroid therapy or transition to rituximab-based treatment as second-line therapy.
Treatment Algorithm for Steroid-Refractory AIHA
Immediate Assessment
When steroids fail to achieve adequate response after 4-6 weeks:
- Confirm the diagnosis is warm AIHA (not cold agglutinin disease or mixed type, as management differs significantly)
- Verify medication adherence
- Assess hemoglobin stability, transfusion requirements, and hemolytic markers
- Rule out secondary causes (lymphoproliferative disorders, autoimmune conditions, infections like HCV/HIV)
Second-Line Treatment Options
Preferred approach: Rituximab
- Dosing: 375 mg/m² weekly for 4 weeks (standard regimen) 1
- Response rates: 70-80% effectiveness in steroid-refractory cases 2
- Rationale: Rituximab has emerged as the preferred second-line therapy, increasingly favored over splenectomy due to lower complication rates 3, 1
- Can be used as monotherapy or combined with low-dose corticosteroids 4
Alternative: Splenectomy
- Historically the standard second-line option
- Effectiveness: ~70% response rate with ~20% achieving cure 2
- Current role: Reserved for patients who fail rituximab or have contraindications to immunosuppression
- Should ideally be delayed at least 12 months from diagnosis when feasible 5
Third-Line Options for Rituximab Failures
If rituximab fails or provides inadequate response, consider:
Immunosuppressive agents (in order of evidence):
Combination therapy: Corticosteroids + cyclophosphamide
Emerging therapies for severe refractory cases:
- B-cell directed therapies
- Complement inhibitors
- Phagocytosis inhibitors 3
Critical Pitfalls to Avoid
Distinguish AIHA subtypes: The evidence provided includes guidelines for acquired hemophilia A and ITP, which are different conditions requiring different management 6, 5. For warm AIHA specifically, corticosteroids remain first-line, but cold agglutinin disease requires rituximab ± bendamustine as first-line therapy (steroids are ineffective) 1, 4.
Steroid duration: Limit corticosteroid use to ≤6 weeks to minimize toxicity 7. Prolonged steroid exposure without response increases infection risk without improving outcomes.
Infection monitoring: Immunosuppressive therapy carries significant infection risk. One registry showed mortality from sepsis (12.2%) exceeded bleeding mortality (3.6%) 6. Monitor closely for neutropenia and opportunistic infections.
Avoid ineffective treatments: Intravenous immunoglobulins are not recommended for warm AIHA 6, though they may have a role in mixed presentations.
Evidence Quality Considerations
The strongest evidence for rituximab in steroid-refractory warm AIHA comes from the 2020 First International Consensus Meeting 1, which represents expert consensus based on available data. However, the authors acknowledge that "there is currently no licensed treatment for AIHA" and recommendations are often based on expert opinion rather than randomized trials due to disease rarity 1.
The 2026 French protocol 4 and recent Asian-Pacific consensus 8 both support corticosteroids ± rituximab as the standard approach, with rituximab increasingly preferred for second-line therapy. Real-world data shows corticosteroid response rates of 81-96% but relapse rates of 18-45% 8, supporting the need for effective second-line options.
For patients with partial steroid response showing clinical stability, consider early addition of rituximab rather than waiting for complete steroid failure, particularly in severe cases requiring ongoing transfusions 1.